A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer

Tongji Hospital1 site in 1 country2,000 target enrollmentMarch 1, 2024

ConditionsOvarian Cancer Biomarker

Overview

Phase: N/A
Intervention: Not specified
Conditions: Ovarian Cancer
Sponsor: Tongji Hospital
Enrollment: 2000
Locations: 1
Primary Endpoint: Biomarker explorarion
Status: Active, Not Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This clinical trial aims to investigate the role of biomarkers in guiding precision treatment for ovarian cancer. The study will explore the effectiveness of personalized treatment strategies based on specific biomarkers identified in ovarian cancer patients. By analyzing the correlation between biomarker profiles and treatment outcomes, the trial seeks to optimize treatment decisions and improve overall survival rates in ovarian cancer patients.

Registry

clinicaltrials.gov

Start Date

March 1, 2024

End Date

December 1, 2028

Last Updated

last year

Study Type

Observational

Sex

Female

Investigators

Sponsor

Tongji Hospital

Responsible Party

Principal Investigator

Qinglei Gao

Professor

Tongji Hospital

Eligibility Criteria

Inclusion Criteria

•Patients diagnosed with ovarian cancer.
•Willingness to undergo biomarker testing.
•Ability to provide informed consent for participation in the study.

Exclusion Criteria

•Inability to comply with study requirements or follow-up visits.
•Previous participation in a conflicting clinical trial.

Outcomes

Primary Outcomes

Biomarker explorarion

Time Frame: 5 years

Blood, tumor, and other samples should be sequenced by RNA-seq, Next-Generation Sequencing, or proteomics to identify specific biomarkers associated with treatment response and prognosis in ovarian cancer.